DIPG is a paediatric brainstem glioma with no cure. Cellular immunotherapy approaches require specific targeting of unique and tumour specific cell surface antigens, however, there is a paucity of known targets for DIPG. In this study we have used a proteomics approach to interrogate an array of patient derived DIPG cell lines to identify potential immunotherapy targets